Prot# TMC125-C229: An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks

Project: Research project

Project Details

StatusFinished
Effective start/end date9/7/05 → 8/12/08

Funding

  • PPD Development (TMC125-C229 // TMC125-C229)
  • Tibotec Pharmaceuticals Ltd. (TMC125-C229 // TMC125-C229)